Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GLB1 | P16278 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002065 | 0.93 | KCNH2 (0.60) | KCNH2GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL10697944 | 0.88 | SMN1; SMN2 (0.49) | KCNH2GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL6944812 | 0.85 | KCNH2 (0.55) | KCNH2GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL29557759 | 0.83 | KCNH2 (0.50) | KCNH2GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL5227695 | 0.83 | SMN1; SMN2 (0.67) | KCNH2GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL14621739 | 0.83 | GNAI3 (0.46) | KCNH2GNAI3GNAO1GNAI1SMN1; SMN2 | |
| SCHEMBL29048042 | 0.81 | SMN1; SMN2 (0.56) | KCNH2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27491245 | 0.81 | BCHE (0.56) | KCNH2GNAI3GNAO1GNAI1SMN1; SMN2 | |
| SCHEMBL13472645 | 0.80 | THRA (0.56) | KCNH2GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL16510984 | 0.80 | BCHE (0.60) | KCNH2GNAI3GNAO1GNAI1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242597-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20170058031-A1 | HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF | SQUIBB & SONS LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9499632-B2 | Human antibodies that bind CD22 and uses thereof | E.R. SQUIBB & SONS, L.L.C. (US) | 2016-11-22 | — | — | US | disclosed |
| US-8865875-B2 | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions | MEDAREX, L.L.C. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130190481-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| US-8425904-B2 | Human antibodies that bind mesothelin, and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-8399623-B2 | Human antibodies that bind mesothelin, and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20130028905-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130028906-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130028904-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-8268970-B2 | Human antibodies that bind mesothelin, and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110280891-A1 | SITE-SPECIFIC ATTACHMENT OF DRUGS OR OTHER AGENTS TO ENGINEERED ANTIBODIES WITH C-TERMINAL EXTENSIONS | E. R. SQUIBB & SONS, L.L.C. | 2011-11-17 | — | — | US | disclosed |
| US-20110262448-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110085970-A1 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
| US-20110020329-A1 | CONJUGATES OF ANTI-RG-1 ANTIBODIES | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028905-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | EPCAM, CD44, MUC1 | KCNH2 3777/4885GNAI3 2451/4885GNAO1 4104/4885 |
| US-20110280891-A1 | SITE-SPECIFIC ATTACHMENT OF DRUGS OR OTHER AGENTS TO ENGINEERED ANTIBODIES WITH C-TERMINAL EXTENSIONS | FCGR2A, FCGR3B, FCGRT | KCNH2 4040/4885GNAI3 961/4885GNAO1 1922/4885 |
| US-20110262448-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | EPCAM, CD44, MUC1 | KCNH2 3777/4885GNAI3 2451/4885GNAO1 4104/4885 |
| US-20110085970-A1 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE | CD2BP2, CD274, CD22 | KCNH2 3181/4885GNAI3 1667/4885GNAO1 2884/4885 |
| US-20170058031-A1 | HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF | CD2BP2, CD22, CD2 | KCNH2 4436/4885GNAI3 1590/4885GNAO1 3164/4885 |
| US-20130028904-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | EPCAM, CD44, MUC1 | KCNH2 3777/4885GNAI3 2451/4885GNAO1 4104/4885 |
| US-20130190481-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | EPCAM, CD44, MUC1 | KCNH2 3777/4885GNAI3 2451/4885GNAO1 4104/4885 |
| US-20110020329-A1 | CONJUGATES OF ANTI-RG-1 ANTIBODIES | GDI1, ARFGAP1, GLG1 | KCNH2 4757/4885GNAI3 84/4885GNAO1 95/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | KCNH2 837/4885GNAI3 492/4885GNAO1 475/4885 |
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | PTK2, PTK2B, LTK | KCNH2 4479/4885GNAI3 1252/4885GNAO1 2861/4885 |
| US-20130028906-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | EPCAM, CD44, MUC1 | KCNH2 3777/4885GNAI3 2451/4885GNAO1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.